Loading the section…

NNVC: financial statements from SEC — TradeAlmanac

NNVC

NanoViricides, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	31/12/2024	30/09/2024
Research and development	1M	1M	993,066	1M	1M	2M
Selling, general and administrative	744,276	1M	803,619	966,905	902,700	1M
Operating expenses	2M	2M	2M	2M	2M	3M
Operating income	−2M	−2M	−2M	−2M	−2M	−3M
Net income	−2M	−2M	−2M	−2M	−2M	−3M
Earnings per share	−0.09	−0.11	−0.10	−0.14	−0.14	−0.23
Earnings per share, diluted	−0.09	−0.11	−0.10	−0.14	−0.14	−0.23
Weighted average shares	22M	20M	17M	16M	15M	14M
Weighted average shares, diluted	22M	20M	17M	16M	15M	14M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	3M	5M	1M	2M	3M	4M	4M	5M
Current assets	3M	5M	1M

Cash flow

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	31/12/2024	30/09/2024
Operating cash flow	—	—	−2M	—	—	−3M
Depreciation and amortisation	127,566	131,016	130,752	189,114

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator